Corbus Pharmaceuticals Holdings, Inc.
CRBP
$7.70
$0.141.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 19.82M | 18.41M | 20.86M | 15.19M | 15.64M |
| Gross Profit | -19.82M | -18.41M | -20.86M | -15.19M | -15.64M |
| SG&A Expenses | 4.49M | 3.56M | 3.56M | 3.97M | 4.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.30M | 21.97M | 24.42M | 19.15M | 19.78M |
| Operating Income | -24.30M | -21.97M | -24.42M | -19.15M | -19.78M |
| Income Before Tax | -22.97M | -20.56M | -23.34M | -17.66M | -16.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.97M | -20.56M | -23.34M | -17.66M | -16.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.97M | -20.56M | -23.34M | -17.66M | -16.98M |
| EBIT | -24.30M | -21.97M | -24.42M | -19.15M | -19.78M |
| EBITDA | -24.26M | -21.92M | -24.37M | -19.10M | -19.69M |
| EPS Basic | -1.23 | -1.25 | -1.90 | -1.44 | -1.39 |
| Normalized Basic EPS | -0.77 | -0.82 | -1.19 | -0.90 | -0.87 |
| EPS Diluted | -1.23 | -1.25 | -1.90 | -1.44 | -1.39 |
| Normalized Diluted EPS | -0.77 | -0.82 | -1.19 | -0.90 | -0.87 |
| Average Basic Shares Outstanding | 18.71M | 16.48M | 12.31M | 12.24M | 12.20M |
| Average Diluted Shares Outstanding | 18.71M | 16.48M | 12.31M | 12.24M | 12.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |